HowShorted

How shorted is Immix Biopharma, Inc.?

More shorted than 94% of the 2,877 ranked US companies

17.92%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
+1.87
5 reports (~10 weeks)
+11.84
Aggregate net short position time series for Immix Biopharma, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 202617.92%+1.87
15 Jul 202616.05%+1.17
30 Jun 202614.88%+7.39
15 Jun 20267.49%−0.13
29 May 20267.62%+1.54
15 May 20266.08%+0.38
30 Apr 20265.70%+0.11
15 Apr 20265.59%−0.29
31 Mar 20265.88%−3.06
13 Mar 20268.94%+0.09
27 Feb 20268.85%−1.37
13 Feb 202610.22%+1.31
30 Jan 20268.91%+2.16
15 Jan 20266.75%+0.47
31 Dec 20256.28%+1.08
15 Dec 20255.20%+1.12
28 Nov 20254.08%+0.55
14 Nov 20253.53%+3.10
15 Aug 20250.43%−0.27
31 Jul 20250.70%–

Frequently asked questions

How shorted is Immix Biopharma, Inc. right now?
17.92% of Immix Biopharma, Inc.'s (IMMX) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.